Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide with or without virtual behavioural intervention for obesity
ACTRN12624000022561Phase 4Not yet recruiting
- Sponsor
- Eucalyptus
- Start
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirzepatide in obesity (2 arms), sponsored by Eucalyptus. Primary endpoints: Body weight, Ratio of fat-free mass to fat mass and 1 more. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12624000022561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000022561.